Second-Generation cell and gene-based therapies: biological advances, clinical outcomes and strategies for capitalisation
Front Cover -- SECOND GENERATION CELL AND GENE-BASED THERAPIES -- SECOND GENERATION CELL AND GENE-BASED THERAPIES -- Copyright -- Contents -- List of Contributors -- Foreword -- Preface -- 1 - Science -- 1 - Innovation S-Curves in Living Drugs Development and Their Commercialisation -- INTRODUCTION...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Weitere Verfasser: | , , |
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
San Diego
Elsevier Science & Technology
2020
|
| Schlagworte: | |
| Online-Zugang: | FUBA2 |
| Zusammenfassung: | Front Cover -- SECOND GENERATION CELL AND GENE-BASED THERAPIES -- SECOND GENERATION CELL AND GENE-BASED THERAPIES -- Copyright -- Contents -- List of Contributors -- Foreword -- Preface -- 1 - Science -- 1 - Innovation S-Curves in Living Drugs Development and Their Commercialisation -- INTRODUCTION -- S-CURVE PATTERNS IN INDUSTRIAL PRODUCT EMERGENCE -- THE BOTTOM-LINE IMPACT OF THE SUCCESSFUL ADOPTION OF A RADICAL INNOVATION -- BLACK SWAN RISK: THE CONSEQUENCES OF NONADOPTION OF A RADICAL INNOVATION -- THE BIG PHARMAS AND RADICAL INNOVATION ADOPTION -- POLICIES AND REGULATORY FRAMEWORKS AS ACCELERATORS OF TECHNOLOGY ADOPTION AND DEPLOYMENT -- PREDICTING TECHNOLOGICAL PROGRESS: CRITICAL INNOVATION CHUNKS OF THE CAR-T S-ŁCURVE -- PERSPECTIVES -- REFERENCES -- 2 - Development and Deployment of Gene Therapies: An ADA- SCID Case Study -- INTRODUCTION -- HISTORY -- Early Development -- Vector Development -- Early ADA-SCID Gene Therapy -- Early Gene Therapy Failures -- First Approvals -- STRIMVELIS DEVELOPMENT -- Strategic Alliance -- Strimvelis Efficacy -- Strimvelis Registry -- Success of Strimvelis -- Vector Improvement -- Collaboration and Division of Expertise -- Treatment Manufacturing -- BUSINESS -- PAYMENT AND REIMBURSEMENT FOR CURATIVE TREATMENTS -- PERSPECTIVES -- Limited Patient Population -- Future Research Funding -- Technology -- ABBREVIATIONS -- ACKNOWLEDGEMENTS -- REFERENCES -- 3 - Therapeutic Potential of Cells of the Immune System -- INTRODUCTION -- γδ T CELLS AND THE RECOGNITION OF MALIGNANT DISEASE - MULTIPLE WEAPONS, MULTIPLE TARGETS -- Vδ2+ T Cells -- Vδ1+ T Cells -- Regulatory γδ T Cells -- Potential for γδ T Cells as Primary Effectors in Immunotherapy of Cancer -- In vivo Activation and Expansion of γδ T Cells -- Autologous γδ T cell Therapy |
| Beschreibung: | Description based on publisher supplied metadata and other sources |
| Beschreibung: | 1 online resource (848 pages) |
| ISBN: | 9780128120330 |
Internformat
MARC
| LEADER | 00000nmm a22000001c 4500 | ||
|---|---|---|---|
| 001 | BV047167607 | ||
| 003 | DE-604 | ||
| 005 | 20211027 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 210226s2020 |||| o||u| ||||||eng d | ||
| 020 | |a 9780128120330 |9 978-0-12-812033-0 | ||
| 035 | |a (OCoLC)1240397948 | ||
| 035 | |a (DE-599)KEP049932462 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-578 | ||
| 100 | 1 | |a Vertès, Alain |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Second-Generation cell and gene-based therapies |b biological advances, clinical outcomes and strategies for capitalisation |c edited by Alain A. Vertès, Devyn M. Smith, Nasib Qureshi, Nathan J. Dowden |
| 264 | 1 | |a San Diego |b Elsevier Science & Technology |c 2020 | |
| 300 | |a 1 online resource (848 pages) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Description based on publisher supplied metadata and other sources | ||
| 520 | 3 | |a Front Cover -- SECOND GENERATION CELL AND GENE-BASED THERAPIES -- SECOND GENERATION CELL AND GENE-BASED THERAPIES -- Copyright -- Contents -- List of Contributors -- Foreword -- Preface -- 1 - Science -- 1 - Innovation S-Curves in Living Drugs Development and Their Commercialisation -- INTRODUCTION -- S-CURVE PATTERNS IN INDUSTRIAL PRODUCT EMERGENCE -- THE BOTTOM-LINE IMPACT OF THE SUCCESSFUL ADOPTION OF A RADICAL INNOVATION -- BLACK SWAN RISK: THE CONSEQUENCES OF NONADOPTION OF A RADICAL INNOVATION -- THE BIG PHARMAS AND RADICAL INNOVATION ADOPTION -- POLICIES AND REGULATORY FRAMEWORKS AS ACCELERATORS OF TECHNOLOGY ADOPTION AND DEPLOYMENT -- PREDICTING TECHNOLOGICAL PROGRESS: CRITICAL INNOVATION CHUNKS OF THE CAR-T S-ŁCURVE -- PERSPECTIVES -- REFERENCES -- 2 - Development and Deployment of Gene Therapies: An ADA- SCID Case Study -- INTRODUCTION -- HISTORY -- Early Development -- Vector Development -- Early ADA-SCID Gene Therapy -- Early Gene Therapy Failures -- First Approvals -- STRIMVELIS DEVELOPMENT -- Strategic Alliance -- Strimvelis Efficacy -- Strimvelis Registry -- Success of Strimvelis -- Vector Improvement -- Collaboration and Division of Expertise -- Treatment Manufacturing -- BUSINESS -- PAYMENT AND REIMBURSEMENT FOR CURATIVE TREATMENTS -- PERSPECTIVES -- Limited Patient Population -- Future Research Funding -- Technology -- ABBREVIATIONS -- ACKNOWLEDGEMENTS -- REFERENCES -- 3 - Therapeutic Potential of Cells of the Immune System -- INTRODUCTION -- γδ T CELLS AND THE RECOGNITION OF MALIGNANT DISEASE - MULTIPLE WEAPONS, MULTIPLE TARGETS -- Vδ2+ T Cells -- Vδ1+ T Cells -- Regulatory γδ T Cells -- Potential for γδ T Cells as Primary Effectors in Immunotherapy of Cancer -- In vivo Activation and Expansion of γδ T Cells -- Autologous γδ T cell Therapy | |
| 653 | 0 | |a Electronic books | |
| 700 | 1 | |a Dowden, Nathan J. |4 ctb | |
| 700 | 1 | |a Smith, Devyn |4 ctb | |
| 700 | 1 | |a Qureshi, Nasib |4 ctb | |
| 776 | 0 | |z 9780128120347 | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9780128120347 |
| 912 | |a ZDB-30-PQE |a ZDB-4-NLEBK | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-032573154 | ||
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=1805909 |l FUBA2 |p ZDB-4-NLEBK |x Aggregator |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804182246796558336 |
|---|---|
| adam_txt | |
| any_adam_object | |
| any_adam_object_boolean | |
| author | Vertès, Alain |
| author2 | Dowden, Nathan J. Smith, Devyn Qureshi, Nasib |
| author2_role | ctb ctb ctb |
| author2_variant | n j d nj njd d s ds n q nq |
| author_facet | Vertès, Alain Dowden, Nathan J. Smith, Devyn Qureshi, Nasib |
| author_role | aut |
| author_sort | Vertès, Alain |
| author_variant | a v av |
| building | Verbundindex |
| bvnumber | BV047167607 |
| collection | ZDB-30-PQE ZDB-4-NLEBK |
| ctrlnum | (OCoLC)1240397948 (DE-599)KEP049932462 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03216nmm a22003731c 4500</leader><controlfield tag="001">BV047167607</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20211027 </controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">210226s2020 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780128120330</subfield><subfield code="9">978-0-12-812033-0</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1240397948</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)KEP049932462</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-578</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Vertès, Alain</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Second-Generation cell and gene-based therapies</subfield><subfield code="b">biological advances, clinical outcomes and strategies for capitalisation</subfield><subfield code="c">edited by Alain A. Vertès, Devyn M. Smith, Nasib Qureshi, Nathan J. Dowden</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">San Diego</subfield><subfield code="b">Elsevier Science & Technology</subfield><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (848 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Description based on publisher supplied metadata and other sources</subfield></datafield><datafield tag="520" ind1="3" ind2=" "><subfield code="a">Front Cover -- SECOND GENERATION CELL AND GENE-BASED THERAPIES -- SECOND GENERATION CELL AND GENE-BASED THERAPIES -- Copyright -- Contents -- List of Contributors -- Foreword -- Preface -- 1 - Science -- 1 - Innovation S-Curves in Living Drugs Development and Their Commercialisation -- INTRODUCTION -- S-CURVE PATTERNS IN INDUSTRIAL PRODUCT EMERGENCE -- THE BOTTOM-LINE IMPACT OF THE SUCCESSFUL ADOPTION OF A RADICAL INNOVATION -- BLACK SWAN RISK: THE CONSEQUENCES OF NONADOPTION OF A RADICAL INNOVATION -- THE BIG PHARMAS AND RADICAL INNOVATION ADOPTION -- POLICIES AND REGULATORY FRAMEWORKS AS ACCELERATORS OF TECHNOLOGY ADOPTION AND DEPLOYMENT -- PREDICTING TECHNOLOGICAL PROGRESS: CRITICAL INNOVATION CHUNKS OF THE CAR-T S-ŁCURVE -- PERSPECTIVES -- REFERENCES -- 2 - Development and Deployment of Gene Therapies: An ADA- SCID Case Study -- INTRODUCTION -- HISTORY -- Early Development -- Vector Development -- Early ADA-SCID Gene Therapy -- Early Gene Therapy Failures -- First Approvals -- STRIMVELIS DEVELOPMENT -- Strategic Alliance -- Strimvelis Efficacy -- Strimvelis Registry -- Success of Strimvelis -- Vector Improvement -- Collaboration and Division of Expertise -- Treatment Manufacturing -- BUSINESS -- PAYMENT AND REIMBURSEMENT FOR CURATIVE TREATMENTS -- PERSPECTIVES -- Limited Patient Population -- Future Research Funding -- Technology -- ABBREVIATIONS -- ACKNOWLEDGEMENTS -- REFERENCES -- 3 - Therapeutic Potential of Cells of the Immune System -- INTRODUCTION -- γδ T CELLS AND THE RECOGNITION OF MALIGNANT DISEASE - MULTIPLE WEAPONS, MULTIPLE TARGETS -- Vδ2+ T Cells -- Vδ1+ T Cells -- Regulatory γδ T Cells -- Potential for γδ T Cells as Primary Effectors in Immunotherapy of Cancer -- In vivo Activation and Expansion of γδ T Cells -- Autologous γδ T cell Therapy</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Electronic books</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dowden, Nathan J.</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Smith, Devyn</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Qureshi, Nasib</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="776" ind1="0" ind2=" "><subfield code="z">9780128120347</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9780128120347</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-30-PQE</subfield><subfield code="a">ZDB-4-NLEBK</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-032573154</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=1805909</subfield><subfield code="l">FUBA2</subfield><subfield code="p">ZDB-4-NLEBK</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV047167607 |
| illustrated | Not Illustrated |
| index_date | 2024-07-03T16:41:53Z |
| indexdate | 2024-07-10T09:04:30Z |
| institution | BVB |
| isbn | 9780128120330 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-032573154 |
| oclc_num | 1240397948 |
| open_access_boolean | |
| owner | DE-578 |
| owner_facet | DE-578 |
| physical | 1 online resource (848 pages) |
| psigel | ZDB-30-PQE ZDB-4-NLEBK |
| publishDate | 2020 |
| publishDateSearch | 2020 |
| publishDateSort | 2020 |
| publisher | Elsevier Science & Technology |
| record_format | marc |
| spelling | Vertès, Alain Verfasser aut Second-Generation cell and gene-based therapies biological advances, clinical outcomes and strategies for capitalisation edited by Alain A. Vertès, Devyn M. Smith, Nasib Qureshi, Nathan J. Dowden San Diego Elsevier Science & Technology 2020 1 online resource (848 pages) txt rdacontent c rdamedia cr rdacarrier Description based on publisher supplied metadata and other sources Front Cover -- SECOND GENERATION CELL AND GENE-BASED THERAPIES -- SECOND GENERATION CELL AND GENE-BASED THERAPIES -- Copyright -- Contents -- List of Contributors -- Foreword -- Preface -- 1 - Science -- 1 - Innovation S-Curves in Living Drugs Development and Their Commercialisation -- INTRODUCTION -- S-CURVE PATTERNS IN INDUSTRIAL PRODUCT EMERGENCE -- THE BOTTOM-LINE IMPACT OF THE SUCCESSFUL ADOPTION OF A RADICAL INNOVATION -- BLACK SWAN RISK: THE CONSEQUENCES OF NONADOPTION OF A RADICAL INNOVATION -- THE BIG PHARMAS AND RADICAL INNOVATION ADOPTION -- POLICIES AND REGULATORY FRAMEWORKS AS ACCELERATORS OF TECHNOLOGY ADOPTION AND DEPLOYMENT -- PREDICTING TECHNOLOGICAL PROGRESS: CRITICAL INNOVATION CHUNKS OF THE CAR-T S-ŁCURVE -- PERSPECTIVES -- REFERENCES -- 2 - Development and Deployment of Gene Therapies: An ADA- SCID Case Study -- INTRODUCTION -- HISTORY -- Early Development -- Vector Development -- Early ADA-SCID Gene Therapy -- Early Gene Therapy Failures -- First Approvals -- STRIMVELIS DEVELOPMENT -- Strategic Alliance -- Strimvelis Efficacy -- Strimvelis Registry -- Success of Strimvelis -- Vector Improvement -- Collaboration and Division of Expertise -- Treatment Manufacturing -- BUSINESS -- PAYMENT AND REIMBURSEMENT FOR CURATIVE TREATMENTS -- PERSPECTIVES -- Limited Patient Population -- Future Research Funding -- Technology -- ABBREVIATIONS -- ACKNOWLEDGEMENTS -- REFERENCES -- 3 - Therapeutic Potential of Cells of the Immune System -- INTRODUCTION -- γδ T CELLS AND THE RECOGNITION OF MALIGNANT DISEASE - MULTIPLE WEAPONS, MULTIPLE TARGETS -- Vδ2+ T Cells -- Vδ1+ T Cells -- Regulatory γδ T Cells -- Potential for γδ T Cells as Primary Effectors in Immunotherapy of Cancer -- In vivo Activation and Expansion of γδ T Cells -- Autologous γδ T cell Therapy Electronic books Dowden, Nathan J. ctb Smith, Devyn ctb Qureshi, Nasib ctb 9780128120347 Erscheint auch als Druck-Ausgabe 9780128120347 |
| spellingShingle | Vertès, Alain Second-Generation cell and gene-based therapies biological advances, clinical outcomes and strategies for capitalisation |
| title | Second-Generation cell and gene-based therapies biological advances, clinical outcomes and strategies for capitalisation |
| title_auth | Second-Generation cell and gene-based therapies biological advances, clinical outcomes and strategies for capitalisation |
| title_exact_search | Second-Generation cell and gene-based therapies biological advances, clinical outcomes and strategies for capitalisation |
| title_exact_search_txtP | Second-Generation cell and gene-based therapies biological advances, clinical outcomes and strategies for capitalisation |
| title_full | Second-Generation cell and gene-based therapies biological advances, clinical outcomes and strategies for capitalisation edited by Alain A. Vertès, Devyn M. Smith, Nasib Qureshi, Nathan J. Dowden |
| title_fullStr | Second-Generation cell and gene-based therapies biological advances, clinical outcomes and strategies for capitalisation edited by Alain A. Vertès, Devyn M. Smith, Nasib Qureshi, Nathan J. Dowden |
| title_full_unstemmed | Second-Generation cell and gene-based therapies biological advances, clinical outcomes and strategies for capitalisation edited by Alain A. Vertès, Devyn M. Smith, Nasib Qureshi, Nathan J. Dowden |
| title_short | Second-Generation cell and gene-based therapies |
| title_sort | second generation cell and gene based therapies biological advances clinical outcomes and strategies for capitalisation |
| title_sub | biological advances, clinical outcomes and strategies for capitalisation |
| work_keys_str_mv | AT vertesalain secondgenerationcellandgenebasedtherapiesbiologicaladvancesclinicaloutcomesandstrategiesforcapitalisation AT dowdennathanj secondgenerationcellandgenebasedtherapiesbiologicaladvancesclinicaloutcomesandstrategiesforcapitalisation AT smithdevyn secondgenerationcellandgenebasedtherapiesbiologicaladvancesclinicaloutcomesandstrategiesforcapitalisation AT qureshinasib secondgenerationcellandgenebasedtherapiesbiologicaladvancesclinicaloutcomesandstrategiesforcapitalisation |